Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

AstraZeneca (AZN) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia. The latest agreement is likely to strengthen AstraZeneca's cardiovascular pipeline, which is being studied for treating various cardiovascular diseases. Image Source: Zacks Investment Research Year to date, shares of AstraZeneca have rallied 14.1% compared with the ...

For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly (LLY) , AstraZeneca (AZN) , Pfizer (PFE) , Sanofi (SNY) and Bayer (BAYRY) .Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly have witness ...

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.Under this agreement, AstraZeneca will gain access to CSPC's preclinical candidate YS2302018, an oral Lp(a) inhibitor. This drug is aimed at developing a new lipid-lowering therapy and can be used as a standalone or combination treatment for various cardiovascular diseases, including in combination with the oral small m ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysisPhase IIIb clinical development of Airsupra was conducted by Avillion under an exclusive clinical co-development agreement with AstraZeneca Airsupra (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in risk of severe asthma exacerbations in patients with intermittent or mild persistent asthma compared to albuterol alone London, UK, 7 October ...

AstraZeneca (AZN) announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).The company is seeking approval for Calquence for the treatment of adult patients with previously untreated MCL, a rare and aggressive form of non-Hodgkin lymphoma. In the MCL indication, Calquence is currently approved for treating adult patients with MCL who have received at least one prior therapy in the United ...

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu for HER2-low metastatic breast cancer.The companies are seeking approval for Enhertu to treat unresectable or metastatic HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting.The sBLA looks to expand the currently approved indication of Enhertu in HER2- ...

AstraZeneca (AZN) stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca’s stock has also outperformed the sector as well as the S&P 500 index, as seen in the chart below. The stock has also been trading above its 200-day moving average since mid-March.AstraZeneca Stock Outperforms Industry, Sector & S&PImage Source: Zacks Investment ResearchAstraZeneca has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinz ...

AstraZeneca (AZN) announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer.The regulatory body has approved Tagrisso for the treatment of unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) in adult patients whose disease has not progressed following treatment with chemoradiotherapy.Following the latest nod, Tagrisso is now indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations, as determined b ...

The drug and biotech sector has outperformed the broader equity market this year, backed by the launch of promising new medicines, pipeline successes and an increase in merger and acquisition (M&A) activity. Obesity drugs of Novo Nordisk and Eli Lilly (LLY) have witnessed tremendous success, which has played a key role in the industry’s outperformance. The Zacks Large Cap Pharmaceuticals industry has outperformed the broader Medical sector as well as the S&P 500 index this year, as seen in the chart below.I ...